Generic competition hits Lundbeck 2019 revenues, but growth expected this year

6 February 2020

Danish CNS specialist Lundbeck (LUND: CO) shares were down 2.3% at 295.40 Danish kroner by late morning today, after it released financial results for 2019, showing that revenues were down 6% at 17.14 billion Danish kroner ($2.53 billion), primarily driven by the loss of exclusivity of Lennox Gastaux syndrome drug Onfi (clobazam).

Core earnings before interest and taxes (EBIT) for 2019 reached 4,976 million kroner, which is a decline of 19% compared to 2018. The core EBIT margin increased significantly to 29.2% in 2019. EBIT for 2019 reached 3,608 million kroner, compared to 5,301 million kroner in 2018. The EBIT margin decreased to 21.2% in 2019, compared to 29.3% in 2018

Lundbeck’s total revenue is expected to reach between DKK 17.4 billion - 18.0 billion kroner in 2020, and EBIT is expected to be in the range between 2.2 billion - 2.7 billion kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK